NCT04170855Active, not recruiting
Kidney Sodium Content in Cardiorenal Patients
Evaluation of Kidney Medullary Sodium Content Using 23Na MRI to Understand and Predict Diuretic Resistance
Source: ClinicalTrials.gov · Last updated 4 May 2026
Brief summary (registry, in English)
Diuretic therapy is the cornerstone of the management of fluid overload in heart failure. Resistance to diuretic therapy is the most common reason for treatment failure in patients affected by the combination of heart failure and kidney disease. Currently, there is no way of predicting whether heart failure patients will develop resistance to diuretic therapy and what dose of diuretic is necessary to overcome diuretic resistance. Answering these questions would allow doctors to be able to prescribe an accurate dose of diuretic therapy to prevent diuretic resistance and potential side effects of an excessive diuretic dose. With magnetic resonance imaging, it is possible to measure the kidney sodium (salt) content and observe the diuretic response in patients with heart failure and kidney disease. The investigators speculate that measuring kidney sodium content will allow to predict diuretic response in these patients. The aim of this study is to compare the kidney sodium content in patients with chronic cardiorenal syndrome with and without diuretic resistance. Secondly, in a sample of patients with diagnosed diuretic resistance,the aim will be to observe the changes in kidney sodium content induced by an additional dose of diuretic therapy and to observe whether these changes are associated with a response to diuretic therapy.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 21 Oct 2019
- Start date
- 20 Oct 2020
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- NCT number
- NCT04170855
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 20 Oct 2020 to the primary completion date, 30 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Liver disease with hepato-renal syndrome
- Kidney malformation leading to chronic kidney disease (for example polycystic kidney)
Lab values
- Hypokalemia (serum potassium \<3.5 mmol/l)
Other
- Additional diuretic types other than spironolactone/epleronone/metolazone/finerenone
- Pregnant, breastfeeding or intending pregnancy
- Unable to provide consent
Who the study is looking for
- Clinico-pathological diagnosis of heart failure
- Age ≥ 18 years
- Estimated GFR ≥ 15 mL/min/1.73m2
- Receiving loop diuretics for at least a week at ≥ 40 mg/day (furosemide) or 2 mg/day (bumetanide), either orally or intravenously
- Willing and able to provide consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Heart Failure Clinic | St. Joseph's Health Care London Coordinator of this site? Confirm its status | London | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.